Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20113176.
- Also identified by DOI 10.1086/650488.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assessed the effect of a 3-month course of pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) in 3 liver transplant patients with chronic active hepatitis E. A virological response was sustained for 6 and 5 months in 2 patients after Peg-IFN-alpha-2a therapy was completed. A relapse was observed in the third patient.
Medical subject headings
- Antiviral Agents
- Hepatitis E
- Hepatitis, Chronic
- Interferon-alpha
- Polyethylene Glycols